Yamada T, et al. - A meta-analysis was conducted to compare the clinical efficacy and safety of biosimilar insulins with those of originator insulins. Researchers performed a random-effects meta-analysis on randomized controlled trials comparing biosimilar and originator insulins in adults with diabetes. No significant differences were found in clinical efficacy and safety, including immune reactions, between biosimilar and originator insulins. Results of this study suggested that biosimilar insulins could increase access to modern insulin therapy and decrease medical costs.